Inventiva S.A. (NASDAQ:IVA) Receives Average Recommendation of “Buy” from Analysts

Inventiva S.A. (NASDAQ:IVA) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is $17.00.

A number of research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Inventiva in a report on Monday, April 1st. Canaccord Genuity Group lifted their price target on shares of Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a report on Monday, April 8th.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new stake in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

IVA opened at $2.63 on Wednesday. The firm has a 50 day moving average price of $3.28 and a 200-day moving average price of $3.62. Inventiva has a twelve month low of $2.52 and a twelve month high of $4.75.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.